Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Cardiovascular Disease and Type 2 Diabetes
Author(s): Martin Berger , Nikolaus Marx , Katharina Marx-Schütt Added: 12 months ago

Cardiovascular Renal Metabolic

Prevention & Chronic Conditions
ACC 26: AI-Based Retinal Imaging for Atherosclerotic Cardiovascular Risk
Author(s): Michael McConnell Added: 1 week ago
ACC.26 – Dr Michael McConnell (Stanford Health Care, Stanford, CA, US) joins us to discuss findings from a prospective, multicentre clinical trial evaluating whether artificial intelligence analysis of retinal images can identify patients at elevated atherosclerotic cardiovascular risk.Findings showed strong sensitivity and specificity in identifying those at risk of ASCVD in a diverse study… View more

Prevention & Chronic Conditions

Digital Health
SOUL: Oral Semaglutide Aids CV Risk in T2D
Added: 2 weeks ago Source:  Radcliffe CVRM
Individuals with type 2 diabetes (T2D) face a high risk of atherosclerotic cardiovascular disease (ASCVD). The SOUL trial (NCT03914326) previously demonstrated that oral semaglutide reduced major adverse cardiovascular events (MACE).² A new post hoc secondary analysis of this trial now provides insight into the mechanisms behind this benefit, detailing the drug's association with changes in key… View more

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
Obesity Management and Cardiovascular Disease
Author(s): Miao Gao , Tanjot Singh , Ramzi Ajjan Added: 3 days ago

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
Between the Sessions with Dr Parwani: VESALIUS-CV, KARDINAL, CHIP-BCIS3 & M
Author(s): Purvi Parwani Added: 1 week ago
Dr Purvi Parwani (Loma Linda University Health, US) recaps the standout science from Day 2 of ACC 2026, a day defined by a central theme: challenging long-held assumptions in cardiology. Her summary focuses on what these updates mean for day-to-day clinical practice, from prevention strategies to interventional decision-making.Prevention and Risk ReductionVESALIUS-CV: Showed a 25% reduction in… View more

Intervention

Prevention & Chronic Conditions
Cardiovascular Risk in NAFLD
Author(s): Paula Luque-Linero , Jose M Guerra Added: 1 year ago

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
AHA 25 Late-breaking Discussion: The VESALIUS-CV Trial
Author(s): Erin A Bohula , Harriette Van Spall Added: 4 months ago
AHA Scientific Sessions 2025 – Late-breaker host Dr Harriette Van Spall (McMaster University, CA) is joined by Dr Erin A Bohula (Brigham & Women's Hospital, US) to discuss the primary results of the VESALIUS-CV trial, a large-scale, phase 3, double-blind, randomised, placebo-controlled study sponsored by Amgen.The VESALIUS-CV trial (NCT03872401) evaluated the impact of evolocumab, a PCSK9… View more

MI/ACS

Prevention & Chronic Conditions
Targeted Lipid Control in Very-high-risk Indian Patients: Expert Insights
Author(s): Kausik Ray , Upendra Kaul , Srinivasa Rao , et al Added: 3 months ago

Guidelines & Statements
Obesity and CKD: The Dual Epidemic in Cardiovascular Health
Author(s): Christopher Henry Grant , Samira Bell Added: 5 months ago

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
CardioNerds @AHA23: ARTESiA: Stroke Risk Reduction in Sub-Clinical AF: Apixaban vs Aspirin
Author(s): Naima Maqsood , Jeff Healey Added: 2 years ago
AHA 2023 — Dr Naima Maqsood, CardioNerds ambassador (Temple University Hospital, US) interviews investigator, Dr Jeff Healey (McMaster University, CA) to outline the findings from a phase 4 trial of apixaban to reduce thromboembolism in patients with subclinical atrial fibrillation (AF).ARTESiA (NCT01938248) aims to determine if apixaban in combination with aspirin can reduce the instance of… View more

Anticoagulation

Electrophysiology & Arrhythmia